Pluristem Therapeutics, Inc. (NASDAQ: PSTI; DAX: PJT) is a bio-therapeutics Company dedicated to the commercialization of non-personalized (allogeneic) stem cell therapy products for the treatment of several severe degenerative, malignant and autoimmune disorders. The Company’s first planned product, PLX-I, targets a $3 billion annual market and is intended to resolve the global shortfall of matched tissue for bone marrow transplantation (BMT). Pluristem also believes its PLacental eXpanded (PLX) cells will be helpful for a variety of other indication, including as a help to patients afflicted with Peripheral Artery Disease (PAD) with critical limb ischemia (CLI).